Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
When redeeming rewards, several factors can influence your choices. Learn what to consider to ensure you get the best value for your points.
17,088 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Macerich faces a retail landscape that’s evolved in 2025. This deep dive breaks down the factors shaping macerich (ma...
A bitcoin miner is branching into AI infrastructure, and the market has taken notice. The plan to turn U.S. sites int...
Energy markets moved on geopolitical headlines, lifting ConocoPhillips stock in intraday trading. This article explai...
As 2025 unfolds, MediWound faces a pivotal year for debt, cash, and milestones. This analysis breaks down what mediwo...
With only $500, you can start building wealth by buying two stocks that look absurdly cheap. This guide explains how ...
Sionna Therapeutics has surged 144% over the past year, drawing attention from growth-minded investors. This article ...
The AI stock story is shifting from last year’s heroes to new winners in 2026. This guide explains why the leadership...
BioCryst faces a pivotal year. This practical guide breaks down what biocryst (bcrx) 2026 earnings could mean for inv...
Investors eye a steady $5,000 per month in dividends as a way to replace part of a paycheck. This report breaks down ...
Nextpower (NXT) 2026 earnings provide a window into the company’s growth engine and future trajectory. This piece bre...
Senior executives are increasingly deferring about $100,000 of pay into non-qualified plans to extend tax-advantaged ...